Pyng Medical Corp

Saving lives by saving time through innovation in resuscitation™

Pyng Medical Enhances Strong Patent Portfolio

March 26th, 2008

Vancouver, BC - Pyng Medical Corp. (PYT: TSX .V) has now received US patent protection (7,347,840) for its proprietary target patch with strain relief for their unique sternal infusion tube, an integral part of the FAST1™ Intraosseous Infusion System. This patch enables the caregiver to quickly locate the infusion site and protects the patient from infection risk or disruption of the infusion tube at the sternum.

“Our customers love our target patch because it makes the sternal placement of FAST1™ very quick, easy and intuitive. We are very pleased to now have this patent-protected, along with the many other unique patented features of FAST1™, which is why we continue to be the world-leaders in sternal line infusion,” said David Christie, President and Chief Executive Officer.

Pyng Medical continues to expand its patent portfolio with additional filings relating to its proprietary award-winning FAST1™ Intraosseous Infusion device. Pyng has also applied for trademark protection on Chest is Best™, reinforcing the benefits of rapid infusion through their unique FAST1 sternal line.

As part of its on-going commitment to technology innovation, Pyng Medical Corp recently released the enhanced FAST1™ system with a re-engineered infusion tube that no longer requires the use of a removal tool. The company is developing next generation intraosseous products and has filed to protect these and related inventions.

FAST1™ is the most rapid, reliable and safe alternative to conventional IV infusion providing lifesaving vascular access for fluid and drug resuscitation in shock and trauma victims. It is the only product able to rapidly deploy into the sternum allowing for delivery of life-saving fluids and drugs to the hearts in seconds.

About Pyng Medical Corp.

Pyng Medical Corporation is the developer and manufacturer of the proprietary, award-winning FAST1™ Intraosseous Infusion System. Earlier this month, Pyng Medical received the exclusive 2008 Medical Device Company of the Year award from LifeSciences BC for its sustained achievements in commercializing the FAST1™. Pyng was also selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006. With expanding markets in North America, Europe and Asia, the FAST1™ has worldwide application for use with hospitals, emergency medical services and military forces.

For More Information

David Christie
Pyng Medical Corp.
(604) 303-7964
www.pyng.com

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.